|
[1] Drug-induced Liver Disease Study Group,Chinese Society of Hepatology,Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol,2015,31(11):1752-1769.(in Chinese)中华医学会肝病学分会药物性肝病学组．药物性肝损伤诊治指南[J]．临床肝胆病杂志，2015,31(11):1752-1769.
|
|
[2] WANG DY,SALEM JE,COHEN JV,et al. Fatal toxic effects associated with immune checkpoint inhibitors:A systematic review and meta-analysis[J]. JAMA Oncol,2018,4(12):1721-1728.
|
|
[3] DEVARBHAVI H,RAJ S,ARADYA VH,et al. Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis:Patient characteristics, causes, and outcome in 36 cases[J]. Hepatology,2016,63(3):993-999.
|
|
[4] FANG WC,ADLER NR,GRAUDINS LV,et al. Drug-induced liver injury is frequently associated with severe cutaneous adverse drug reactions:Experience from two Australian tertiary hospitals[J]. Intern Med J,2018,48(5):549-555.
|
|
[5] KARDAUN SH,SEKULA P,VALEYRIE-ALLANORE L,et al.Drug reaction with eosinophilia and systemic symptoms(DRESS):An original multisystem adverse drug reaction. Results from the prospective RegiSCAR study[J]. Br J Dermatol,2013,169(5):1071-1080.
|
|
[6] DONG S,HU S,CAI Q. Mechanism of fatal toxic effect associated with immune checkpoint inhibitors and its individualized management[J]. China Cancer,2019,28(6):440-444.(in Chinese)董爽，胡胜，蔡茜．免疫检查点致死性副作用的机制和个体化处理[J]．中国肿瘤，2019,28(6):440-444.
|
|
[7] POSTOW MA,SIDLOW R,HELLMANN MD. Immune-related adverse events associated with immune checkpoint blockade[J]. N Engl J Med,2018,378(2):158-168.
|
|
[8] WALSH S,DIAZ-CANO S,HIGGINS E,et al. Drug reaction with eosinophilia and systemic symptoms:Is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases[J]. Br J Dermatol,2013,168(2):391-401.
|
|
[9] IVERSEN MB,REINERT LS,THOMSEN MK,et al. An innate antiviral pathway acting before interferons at epithelial surfaces[J]. Nat Immunol,2016,17(2):150-158.
|
|
[10] KIRKWOOD JM,BENDER C,AGARWALA S,et al. Mechanisms and management of toxicities associated with highdose interferon alfa-2b therapy[J]. J Clin Oncol,2002,20(17):3703-3718.
|
|
[11] REKER D,BLUM SM,STEIGER C,et al．“Inactive”ingredients in oral medications[J]. Sci Transl Med,2019,11(483):eaau6753.
|
|
[12] LIU M,YANG XZ,YU YC. Current status of the pathogenesis,diagnosis,and treatment of drug-induced cholestasis[J]. J Clin Hepatol,2019,35(2):252-256.(in Chinese)刘梦，杨玄子，于乐成．胆汁淤积型药物性肝损伤的发病机制及诊治[J]．临床肝胆病杂志，2019,35(2):252-256.
|
|
[13] YU YC,FAN Y,CHEN CW. Diagnosis and treatment of druginduced liver injury[J]. J Clin Hepatol,2018,34(6):1160-1165.(in Chinese)于乐成，范晔，陈成伟．药物性肝损伤的诊断和治疗[J]．临床肝胆病杂志，2018,34(6):1160-1165.
|
|
[14] ULLDEMOLINS M,ROBERTS JA,RELLO J,et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically il patients[J]. Clin Pharmacokinet,2011,50(2):99-110.
|
|
[15] LI XX,DU FY,LIU HX,et al. Investigation of the active components in Tripterygium wilfordii leading to its acute hepatotoxicty and nephrotoxicity[J]. J Ethnopharmacol,2015,162:238-243.
|
|
[16] European Association for the Study of the Liver. EASL clinical practice guidelines:Drug-induced liver injury[J]. J Hepatol,2019,70(6):1222-1261.
|
DownLoad: